Shopping Cart
- Remove All
Your shopping cart is currently empty
PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $42 | In Stock | |
| 5 mg | $98 | In Stock | |
| 10 mg | $156 | In Stock | |
| 25 mg | $278 | In Stock | |
| 50 mg | $446 | In Stock | |
| 100 mg | $662 | In Stock |
| Description | PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction. |
| In vitro | METHODS: CAL27 and FaDu cells were treated with HS-173, erlotinib, and PRI-724 (0-100 μM, 48 hours), and cell viability was analyzed by resazurin assay. RESULTS The combination of PRI-724 and HS-173 synergistically reduced the viability of FaDu cells; in CAL27 cells, the best inhibitory results were observed with the mixture of PRI-724 and erlotinib. [2] |
| In vivo | METHODS: HCV transgenic mice were treated with PRI-724 (5, 20 mg/kg, intraperitoneally, once a day, for 6 weeks) intraperitoneally, and the antifibrotic activity of PRI-724 against HCV-induced liver fibrosis was evaluated. RESULTS In HCV transgenic mice, the expression of S100A4, which is controlled by CBP/β-catenin, was increased; this induction was attenuated by the administration of PRI-724, and the HCV-induced increase in hepatic hydroxyproline was also attenuated. Inhibition of CBP/β-catenin by PRI-724 is effective against HCV-induced liver fibrosis. [1] METHODS: HCV transgenic mice were treated with PRI-724 (0.1, 0.3, 1 mg/kg, subcutaneous injection, 6 weeks) to evaluate the anti-fibrotic activity of PRI-724. RESULTS PRI-724 can effectively reduce the area of collagen fibers in the liver in a dose-dependent manner and increase the expression level of Mmp8 mRNA and the number of F4/80, Ly-6C and Gr-1 positive cells. [1] |
| Synonyms | Foscenvivint, C-82 prodrug |
| Molecular Weight | 658.64 |
| Formula | C33H35N6O7P |
| Cas No. | 1422253-38-0 |
| Smiles | C([C@@H]1N2[C@@](N(C(NCC3=CC=CC=C3)=O)N(C)CC2=O)([C@H](C)N(CC=4C5=C(C=CC4)C=CC=N5)C1=O)[H])C6=CC=C(OP(=O)(O)O)C=C6 |
| Relative Density. | 1.48 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (83.51 mM), Sonication is recommended. Ethanol: 1.8 mg/mL (2.73 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.04 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.